BE839625A - Procede pour l'enrobage enterique de medicaments ainsi enrobes - Google Patents
Procede pour l'enrobage enterique de medicaments ainsi enrobesInfo
- Publication number
- BE839625A BE839625A BE165217A BE165217A BE839625A BE 839625 A BE839625 A BE 839625A BE 165217 A BE165217 A BE 165217A BE 165217 A BE165217 A BE 165217A BE 839625 A BE839625 A BE 839625A
- Authority
- BE
- Belgium
- Prior art keywords
- solution
- acetone
- drug
- mixture
- solvent
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 25
- 230000008569 process Effects 0.000 title claims description 6
- 229940126601 medicinal product Drugs 0.000 title claims description 3
- 239000002702 enteric coating Substances 0.000 title description 4
- 238000009505 enteric coating Methods 0.000 title description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 47
- 239000003814 drug Substances 0.000 claims description 31
- 239000011248 coating agent Substances 0.000 claims description 24
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 23
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 17
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 11
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 10
- 239000013081 microcrystal Substances 0.000 claims description 10
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 9
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 239000004014 plasticizer Substances 0.000 claims description 5
- 229960002380 dibutyl phthalate Drugs 0.000 claims description 4
- 239000003684 drug solvent Substances 0.000 claims description 4
- 239000002966 varnish Substances 0.000 claims description 4
- 229920006318 anionic polymer Polymers 0.000 claims description 3
- 125000000129 anionic group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000005292 vacuum distillation Methods 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 1
- 239000000243 solution Substances 0.000 description 26
- 238000000576 coating method Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229960003276 erythromycin Drugs 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 7
- 230000008025 crystallization Effects 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000004051 gastric juice Anatomy 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000003507 refrigerant Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU72439A LU72439A1 (enrdf_load_stackoverflow) | 1975-05-09 | 1975-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE839625A true BE839625A (fr) | 1976-07-16 |
Family
ID=19727929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE165217A BE839625A (fr) | 1975-05-09 | 1976-03-16 | Procede pour l'enrobage enterique de medicaments ainsi enrobes |
Country Status (2)
| Country | Link |
|---|---|
| BE (1) | BE839625A (enrdf_load_stackoverflow) |
| LU (1) | LU72439A1 (enrdf_load_stackoverflow) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5651983A (en) * | 1993-02-26 | 1997-07-29 | The Procter & Gamble Company | Bisacodyl dosage form for colonic delivery |
| US5686106A (en) * | 1995-05-17 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form for colonic delivery |
| US5843479A (en) * | 1993-02-26 | 1998-12-01 | The Procter & Gamble Company | Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
| US5914132A (en) * | 1993-02-26 | 1999-06-22 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1115596B (it) * | 1978-03-13 | 1986-02-03 | Bayer Italia Spa | Metodo per la preparazione di microgranuli gastoresistenti ed enterosolubili di sostanze farmaceutiche,in particolare di sostanze proteiche e microgranuli preparati con detto metodo |
| FR2476485A1 (fr) * | 1980-02-26 | 1981-08-28 | Roussel Uclaf | Nouveau procede d'enrobage d'au moins un principe actif medicamenteux, les nouveaux medicaments ainsi obtenus, et les compositions les renfermant |
-
1975
- 1975-05-09 LU LU72439A patent/LU72439A1/xx unknown
-
1976
- 1976-03-16 BE BE165217A patent/BE839625A/fr not_active IP Right Cessation
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5651983A (en) * | 1993-02-26 | 1997-07-29 | The Procter & Gamble Company | Bisacodyl dosage form for colonic delivery |
| US5843479A (en) * | 1993-02-26 | 1998-12-01 | The Procter & Gamble Company | Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
| US5914132A (en) * | 1993-02-26 | 1999-06-22 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| US5686106A (en) * | 1995-05-17 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form for colonic delivery |
Also Published As
| Publication number | Publication date |
|---|---|
| LU72439A1 (enrdf_load_stackoverflow) | 1977-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0385846B1 (fr) | Composition pharmaceutique à libération prolongée d'acide valproîque | |
| EP0624371B1 (fr) | Microcapsules pour la libération contrôlée d'acide acétylsalicylique | |
| FR2484834A1 (fr) | Composition pharmaceutique contenant des sels d'aluminium de l'ibuprofene | |
| FR2630912A1 (fr) | Composition permettant d'administrer un medicament sous forme de gelules, d'une poudre ou d'un liquide | |
| FR2484254A1 (fr) | Compositions pharmaceutiq | |
| CH647676A5 (fr) | Formes galeniques a usage oral, a liberation programmee et leurs procedes de preparation. | |
| JP2000515871A (ja) | トラマドール複式ユニット製剤 | |
| FR2602423A1 (fr) | Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede | |
| WO1988006457A1 (en) | Medicinal composition containing albumin as carrier and process for its preparation | |
| FR2615101A1 (fr) | Composition pharmaceutique a base de cefuroxime axetil et sa preparation | |
| US9918941B2 (en) | Method for producing enteric alginate microcapsules via ionic gelation containing diclofenac or one of the salts thereof and multiparticled pharmaceutical composition containing them | |
| JPH0632739A (ja) | 胆汁酸の小ペレットを含有する徐放性経口薬剤組成物 | |
| FR2541287A1 (fr) | Preparation stable administrable par voie orale de macrolides antibiotiques et procede pour les stabiliser | |
| BE839625A (fr) | Procede pour l'enrobage enterique de medicaments ainsi enrobes | |
| FR2540727A1 (fr) | Nouvelle preparation retard contenant de la n''-cyano-n-4-pyridyl-n'-1,2,2-trimethylpropylguanidine, utile notamment dans le traitement de l'hypertension | |
| TW550087B (en) | Solubilized sertraline compositions | |
| US3784683A (en) | Tablet preparation | |
| FR2492259A1 (fr) | Formulation d'heparine | |
| EP0036345B1 (fr) | Nouveau procédé d'enrobage d'au moins un principe actif médicamenteux, les nouveaux médicaments ainsi obtenus, et les compositions les renfermant | |
| FR2753097A1 (fr) | Gel aqueux ou hydroalcoolique extemporane a viscosite controlee | |
| RU2160095C2 (ru) | ТАБЛЕТКИ ДИАЗОЛИНА, ПОЛУЧЕННЫЕ НА ОСНОВЕ КОМПЛЕКСА ВКЛЮЧЕНИЯ СУБСТАНЦИИ С β-ЦИКЛОДЕКСТРИНОМ, ОБЛАДАЮЩИЕ АНТИГИСТАМИННЫМ ДЕЙСТВИЕМ | |
| CN1969829A (zh) | 包封氯氮平的固体脂质微颗粒及其制备方法 | |
| CA2022447A1 (fr) | Forme galenique orale ameliorant la biodisponibilite | |
| JPS61152623A (ja) | トリプトフアンのマイクロカプセル | |
| FR2518880A1 (fr) | Compositions therapeutiques a activite choleretique, contenant a titre de principe actif, des derives de l'acide cholanique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE | Patent lapsed |
Owner name: CENTRE EUROPEEN DE RECHERCHES THERAPEUTIQUES APPL Effective date: 19840316 |